FR2549051B1
(en)
|
1983-06-22 |
1986-05-16 |
Centre Nat Rech Scient |
NOVEL RADIOPROTECTIVE AGENTS HAVING AN AMINO-THIOALKYL STRUCTURE AND PROCESS FOR THEIR PREPARATION
|
US5262319A
(en)
|
1985-04-19 |
1993-11-16 |
Oncogene Science, Inc. |
Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
|
WO1990000194A1
(en)
|
1988-06-28 |
1990-01-11 |
La Jolla Cancer Research Foundation |
Suppression of cell proliferation by decorin
|
US5705609A
(en)
|
1988-06-28 |
1998-01-06 |
La Jolla Cancer Research Foundation |
Decorin fragments inhibiting cell regulatory factors
|
US5654270A
(en)
|
1988-06-28 |
1997-08-05 |
La Jolla Cancer Research Foundation |
Use of fibromodulin to prevent or reduce dermal scarring
|
US5583103A
(en)
|
1988-06-28 |
1996-12-10 |
La Jolla Cancer Research Foundation |
Inhibition of transforming growth factor beta activity
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
CA2065860C
(en)
|
1989-09-29 |
2001-03-27 |
Wayne A. Border |
Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix
|
DE69024369T2
(en)
|
1989-11-22 |
1996-06-13 |
Genentech, Inc., South San Francisco, Calif. |
LATENCY ASSOCIATED PEPTIDES AND THEIR USE
|
WO1991010727A1
(en)
|
1990-01-22 |
1991-07-25 |
La Jolla Cancer Research Foundation |
Inhibitors of cell regulatory factors
|
US5554655A
(en)
|
1991-09-30 |
1996-09-10 |
Jess G. Thoene |
Method of treating HIV infection
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
DE69232986T2
(en)
|
1991-10-31 |
2003-12-11 |
Whitehead Institute For Biomedical Research, Cambridge |
TGF-BETA TYPE III RECEPTOR, FOR CODING CDNS AND THEIR USE
|
WO1993009800A1
(en)
|
1991-11-14 |
1993-05-27 |
La Jolla Cancer Research Foundation |
Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
|
GB9205800D0
(en)
|
1992-03-17 |
1992-04-29 |
British Tech Group |
Treatment of fibrotic disorders
|
US5869462A
(en)
|
1992-09-10 |
1999-02-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
US5821234A
(en)
|
1992-09-10 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
AU5587094A
(en)
|
1992-10-26 |
1994-05-24 |
Kirin Brewery Company, Limited |
Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
|
ES2174868T3
(en)
|
1992-10-29 |
2002-11-16 |
Celtrix Pharma |
FRAGMENT OF THE FIXING RECEIVER TO TGF-BETA TIPOII AS A THERAPEUTIC AGENT.
|
WO1994010187A1
(en)
|
1992-10-30 |
1994-05-11 |
Hsc Research And Development Limited Partnership |
COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b)
|
US5830847A
(en)
|
1992-10-30 |
1998-11-03 |
Hsc Research & Development Limited Partnership |
Soluble TGF-β-binding endoglin polypeptides and homodimers
|
ATE235549T1
(en)
|
1993-04-30 |
2003-04-15 |
Biognostik Ges |
ANTISENSE OLIGONUCLEOTIDES FOR TREATING IMMUNOSUPPRESSIVE EFFECTS OF TGF-BETA2
|
EP0737071A1
(en)
|
1993-06-15 |
1996-10-16 |
Il- Yang Pharm. Co., Ltd. |
Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
|
WO1995010610A1
(en)
|
1993-10-15 |
1995-04-20 |
La Jolla Cancer Research Foundation |
BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
|
EP0758452B1
(en)
|
1994-05-04 |
2001-11-07 |
Mount Sinai Hospital Corporation |
Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
|
US5772995A
(en)
|
1994-07-18 |
1998-06-30 |
Sidney Kimmel Cancer Center |
Compositions and methods for enhanced tumor cell immunity in vivo
|
CA2156767A1
(en)
|
1994-08-25 |
1996-02-26 |
Kenichi Matsunaga |
Binding agent for growth factor
|
JPH08119984A
(en)
|
1994-08-31 |
1996-05-14 |
Nkk Corp |
Actinomyces blonging to genus streptomyces and tgf-beta inhibitor derived from the same actinomyces
|
US5824655A
(en)
|
1995-02-15 |
1998-10-20 |
The University Of Utah |
Anti-transforming growth factor-β gene therapy
|
US5714519A
(en)
|
1995-06-07 |
1998-02-03 |
Ergo Science Incorporated |
Method for regulating glucose metabolism
|
GB9601081D0
(en)
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
EP0921809A4
(en)
|
1996-04-30 |
2001-10-24 |
Genzyme Corp |
Use of prolactin as a tgf-beta antagonist
|
JPH1067674A
(en)
|
1996-06-19 |
1998-03-10 |
Advanced Sukin Res Kenkyusho:Kk |
Abnormal accumulation suppressor of extracellular matrix
|
WO1998017304A1
(en)
|
1996-10-25 |
1998-04-30 |
Johnson & Johnson Medical, Inc. |
Anti-fibrotic agent assay
|
CN1257545A
(en)
|
1997-04-18 |
2000-06-21 |
拜奥根有限公司 |
Type II TGF-beta receptor/immunoglobulin constant region fusion proteins
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
US6468522B1
(en)
|
1999-07-22 |
2002-10-22 |
University Of Medicine And Dentistry Of New Jersey |
Controlled release of thioamide moiety-containing therapeutic agents
|
US6521266B1
(en)
|
1999-09-23 |
2003-02-18 |
Morris A. Mann |
Composition for growth hormone production and release, appetite suppression, and methods related thereto
|
GB0102665D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
EP1363904A1
(en)
|
2001-02-02 |
2003-11-26 |
Glaxo Group Limited |
Pyrazoles as tgf inhibitors
|
GB0102672D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
US20040087623A1
(en)
|
2001-02-02 |
2004-05-06 |
Gellibert Francoise Jeanne |
Pyrazole derivatives against tgf overexpression
|
GB0102668D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
GB0102673D0
(en)
|
2001-02-02 |
2001-03-21 |
Glaxo Group Ltd |
Compounds
|
CN1951939A
(en)
|
2001-05-24 |
2007-04-25 |
伊莱利利公司 |
Novel pyrrole derivatives as pharmaceutical agents
|
AR039241A1
(en)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
|
JP2005530800A
(en)
|
2002-05-15 |
2005-10-13 |
スミスクライン・ビーチャム・コーポレイション |
Benzoxazine and benzoxazinone substituted triazoles
|
US20040038856A1
(en)
|
2002-05-17 |
2004-02-26 |
Sarvajit Chakravarty |
Treatment of fibroproliferative disorders using TGF-beta inhibitors
|
WO2004010929A2
(en)
|
2002-07-25 |
2004-02-05 |
Scios, Inc. |
METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
|
GB0217786D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Compounds
|
UA80296C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
UA80295C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
RU2005110656A
(en)
|
2002-09-10 |
2006-01-20 |
Сайос Инк. (Us) |
TGF INHIBITORS
|
ES2291664T3
(en)
|
2002-09-17 |
2008-03-01 |
Eli Lilly And Company |
DERIVATIVES OF PIRAZOLOPIRIDINE AS INHIBITORS OF TGF BETA SIGNAL TRANSDUCTION FOR CANCER TREATMENT.
|
WO2004026302A1
(en)
|
2002-09-19 |
2004-04-01 |
Eli Lilly And Company |
Methods of inhibiting tgf beta with substituted pyrazoles
|
US20060079680A1
(en)
|
2002-11-22 |
2006-04-13 |
Eli Lilly And Company Patent Division |
Pyrazoloazepine compounds as pharmaceutical agents
|
UA80571C2
(en)
|
2002-11-22 |
2007-10-10 |
Lilly Co Eli |
Quinolinyl-pyrrolopyrazoles
|
US20040138188A1
(en)
|
2002-11-22 |
2004-07-15 |
Higgins Linda S. |
Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
|
AU2003294471A1
(en)
|
2002-11-22 |
2004-06-18 |
Scios, Inc. |
METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ss-ADRENERGIC PATHWAY
|
US7405299B2
(en)
|
2002-11-27 |
2008-07-29 |
Eli Lilly And Company |
Compounds as pharmaceutical agents
|
EP1589960A4
(en)
|
2002-12-19 |
2008-09-10 |
Scios Inc |
Treatment of obesity and associated conditions with tgf-beta inhibitors
|
CL2004000234A1
(en)
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
DERIVATIVE COMPOUNDS 3- (PIRIDIN-2-IL) -4-HETEROARIL-PIRAZOL SUBSTITUTED, ANTAGONISTS OF AIK5 AND / OR AIK4; PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND IN THE TREATMENT OF FIBROTIC DISORDERS AS SCLERODERMIA, LUPUS NEFRITICO, CICATRIZACION DE HERID
|
CA2520465A1
(en)
|
2003-03-28 |
2004-10-14 |
Scios Inc. |
Bi-cyclic pyrimidine inhibitors of tgf.beta.
|
EP1646655A2
(en)
|
2003-07-09 |
2006-04-19 |
Eli Lilly And Company |
Tgf-beta1 ligands
|
WO2005032481A2
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
RU2006122519A
(en)
|
2003-12-24 |
2008-01-27 |
Сайос, Инк. (Us) |
TREATMENT OF MALIGNANT GLIOMAS BY TGF-BETA INHIBITORS
|
WO2005092894A1
(en)
|
2004-03-01 |
2005-10-06 |
Eli Lilly And Company |
Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
|
JP5128935B2
(en)
|
2004-03-31 |
2013-01-23 |
ジェネンテック, インコーポレイテッド |
Humanized anti-TGF-β antibody
|
DE102004019253A1
(en)
|
2004-04-16 |
2005-11-10 |
Codewrights Gmbh |
Method for remote control of a field device of process automation technology
|
US20080171755A1
(en)
|
2004-08-31 |
2008-07-17 |
Wen-Cherng Lee |
Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
|
JP2008511631A
(en)
|
2004-08-31 |
2008-04-17 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Pyrimidinylimidazoles as TGF-β inhibitors
|
WO2006052568A2
(en)
|
2004-11-10 |
2006-05-18 |
Eli Lilly And Company |
Tgf-beta inhibitors
|
BRPI0607639B1
(en)
|
2005-02-08 |
2022-04-05 |
Genzyme Corporation |
Human antibody molecules or antigen-binding fragments thereof that bind and neutralize tgf-beta1, 2 and 3, their use and pharmaceutical composition
|
US8026284B2
(en)
|
2006-01-27 |
2011-09-27 |
The Regents Of The University Of California |
Enterically coated cystamine, cysteamine and derivatives thereof
|
WO2008070117A1
(en)
*
|
2006-12-04 |
2008-06-12 |
Promedior, Inc. |
Conjoint therapy for treating fibrotic diseases
|
MY156316A
(en)
*
|
2007-11-30 |
2016-02-11 |
Univ California |
Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
|